硬化療法市場機會、成長動力、產業趨勢分析與 2025 - 2034 年預測

2024 年全球硬化療法市場價值為 13 億美元，預計 2025 年至 2034 年期間將以 6.1% 的強勁年複合成長率(CAGR) 成長。 這一成長主要得益於血管疾病患病率的不斷上升、對微創治療方案的偏好日益增加、先進硬化劑的監管方案以及先進硬化劑的監管方案作為廣泛的經濟應用。

市場分為化學促效劑、洗滌劑和滲透劑。 2024 年，洗滌劑領域佔據市場主導地位，佔有 68.1% 的佔有率。與其他類型的硬化劑相比，清潔劑由於其高效性、保護性和靈活性而成為首選。流行的清潔劑，例如聚多卡醇和十四烷基硫酸鈉，廣泛用於靜脈曲張和蜘蛛靜脈的美容和醫療治療。與滲透劑和化學刺激物相比，這些藥物引起併發症（包括過敏反應和色素沉澱）的風險較低。

硬化療法市場也分為泡沫硬化療法、液體硬化療法、超音波硬化療法和其他療法。 2024 年，液體硬化療法領域佔 46.9% 的市佔率。液體硬化療法因其多功能性、成本效益以及適合治療較小的靜脈（例如蜘蛛靜脈）而受到青睞。與基於泡沫的治療方法或先進的治療方法相比，它是一種更實惠的選擇，預算有限的患者和診所也可以接受。此外，液體硬化療法用於較小的靜脈時，發生栓塞等副作用的風險較低，因此是一種更安全的替代方法。過程本身很簡單，只需要極少的準備，與泡沫或其他療法相比，這進一步增加了它的吸引力。

在美國，2024年硬化療法市場價值為4.83億美元。此外，美國擁有完善的醫療保健基礎設施，擁有配備硬化療法設備的專門醫院和診所。超音波等先進的診斷工具進一步提高了治療的精確度和有效性，促進了市場的強勁表現。

目錄

第 1 章：方法論與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業衝擊力
  • 成長動力
    • 血管疾病盛行率不斷上升
    • 微創治療程序需求不斷成長
    • 晚期硬化劑的監管批准
    • 擴大採用這種方法作為手術的經濟有效的替代方案
  • 產業陷阱與挑戰
    • 與不良反應和併發症相關的增加
    • 缺乏報銷保障
• 成長潛力分析
• 專利分析
• 差距分析
• 監管格局
• 技術格局
• 未來市場趨勢
• 波特的分析
• PESTEL 分析

第4章：競爭格局

• 介紹
• 公司市佔率分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 策略展望

第 5 章：市場估計與預測：按代理商，2021 年至 2034 年

• 主要趨勢
• 清潔劑
• 化學刺激物
• 滲透劑

第 6 章：市場估計與預測：按療法，2021 – 2034 年

• 主要趨勢
• 液體硬化療法
• 超音波硬化療法
• 泡沫硬化療法
• 其他療法

第 7 章：市場估計與預測：按應用，2021 年至 2034 年

• 主要趨勢
• 靜脈曲張
• 痔瘡
• 畸形淋巴管
• 鞘膜積液
• 其他應用

第 8 章：市場估計與預測：按地區，2021 年至 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第9章：公司簡介

• AngioDynamics
• Bioniche Pharma Group
• Boston Scientific Corporation
• Changan Tianyu group
• Chemische Fabrik Kreussler
• Cook Medical
• Endo-Flex (Meditek Systems)
• Erbe Elektromedizin
• LGM Pharma
• Medtronic
• MTW ENDOSKOPIE
• Omega Labs
• Perrigo Company
• Samarth Life Sciences
• Troikaa Pharmaceuticals

The Global Sclerotherapy Market was valued at USD 1.3 billion in 2024 and is projected to grow at a robust compound annual growth rate (CAGR) of 6.1% from 2025 to 2034. This growth is primarily fueled by the increasing prevalence of vascular disorders, a rising preference for minimally invasive treatment options, regulatory approvals for advanced sclerosants, and the expanding use of sclerotherapy as a cost-effective alternative to surgery.

The market is segmented into chemical irritants, detergents, and osmotic agents. In 2024, the detergents segment led the market with a dominant share of 68.1%. Detergents are the preferred choice due to their high efficiency, protective profile, and flexibility compared to other types of sclerosing agents. Popular detergents, such as polidocanol and sodium tetradecyl sulfate, are widely used for both cosmetic and medical treatments of varicose and spider veins. These agents are known for their lower risk of complications, including allergic reactions and hyperpigmentation when compared to osmotic agents and chemical irritants.

The sclerotherapy market is also divided into foam sclerotherapy, liquid sclerotherapy, ultrasound sclerotherapy, and other therapies. In 2024, the liquid sclerotherapy segment accounted for 46.9% of the market share. Liquid sclerotherapy is favored for its versatility, cost-effectiveness, and suitability for treating smaller veins, such as spider veins. As a more affordable option compared to foam-based or advanced treatments, it is accessible to patients and clinics with budget constraints. Additionally, liquid sclerotherapy carries a lower risk of side effects, such as embolization, when used for smaller veins, making it a safer alternative. The procedure itself is straightforward and requires minimal preparation, further adding to its appeal compared to foam or other therapies.

In the United States, the sclerotherapy market was valued at USD 483 million in 2024. The high prevalence of vascular diseases across the country is a key factor driving revenue growth in the market. Additionally, the U.S. benefits from a well-established healthcare infrastructure, with specialized hospitals and clinics equipped to perform sclerotherapy. Access to advanced diagnostic tools, such as ultrasound, further enhances the precision and effectiveness of treatments, contributing to the market's strong performance.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of vascular disorders
    • 3.2.1.2 Rising demand for minimally invasive therapeutic procedures
    • 3.2.1.3 Regulatory approval of advanced sclerosants
    • 3.2.1.4 Increasing adoption as a cost-effective alternative to surgery
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Rise related to adverse reactions and complications
    • 3.2.2.2 Lack of reimbursement coverage
• 3.3 Growth potential analysis
• 3.4 Patent analysis
• 3.5 Gap analysis
• 3.6 Regulatory landscape
• 3.7 Technological landscape
• 3.8 Future market trends
• 3.9 Porter’s analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy outlook

Chapter 5 Market Estimates and Forecast, By Agents, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Detergents
• 5.3 Chemical irritants
• 5.4 Osmotic agents

Chapter 6 Market Estimates and Forecast, By Therapy, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Liquid sclerotherapy
• 6.3 Ultrasound sclerotherapy
• 6.4 Foam sclerotherapy
• 6.5 Other therapies

Chapter 7 Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Varicose veins
• 7.3 Hemorrhoids
• 7.4 Malformed lymph vessels
• 7.5 Hydroceles
• 7.6 Other applications

Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 AngioDynamics
• 9.2 Bioniche Pharma Group
• 9.3 Boston Scientific Corporation
• 9.4 Changan Tianyu group
• 9.5 Chemische Fabrik Kreussler
• 9.6 Cook Medical
• 9.7 Endo-Flex (Meditek Systems)
• 9.8 Erbe Elektromedizin
• 9.9 LGM Pharma
• 9.10 Medtronic
• 9.11 MTW ENDOSKOPIE
• 9.12 Omega Labs
• 9.13 Perrigo Company
• 9.14 Samarth Life Sciences
• 9.15 Troikaa Pharmaceuticals